PedAM
Pediatric Disease Annotations & Medicines
| Disease | hypoglycemia |
| Phenotype | C0011860|type 2 diabetes |
| Sentences | 135 |
| PubMedID- 26484727 | Results: in type 2 diabetesinsulin naive participants, risk of nocturnal hypoglycaemia was significantly lower with insulin degludec vs. |
| PubMedID- 23900589 | Objective: we examined the association between hba1c level and self-reported severe hypoglycemia in patients with type 2 diabetes. |
| PubMedID- 23683002 | Aim: to compare the impact of diabetes duration on hypoglycaemia in patients with type 2 diabetes mellitus (t2dm) treated with insulin glargine or nph insulin. |
| PubMedID- 24033863 | Aims: we aimed to identify predictors of hypoglycaemia in patients with poorly controlled type 2 diabetes treated with a single daily bolus of insulin glulisine on top of insulin glargine and oral antidiabetic drugs (basal-plus regimen). |
| PubMedID- 25937182 | Increasing trend in emergency department visits for hypoglycemia from patients with type 2 diabetes mellitus in taiwan. |
| PubMedID- 24812495 | Conclusion: symptomatic hypoglycemia in patients with type 2 diabetes on metformin and sulfonylureas was associated with nonadherence and decreased treatment satisfaction despite lower mean hba1c values. |
| PubMedID- 21437076 | Minimizing the risk of hypoglycemia in patients with type 2 diabetes mellitus. |
| PubMedID- 25316712 | Minimizing the occurrence of hypoglycemia in patients with type 2 diabetes is a challenging task since these patients typically check only 1 to 2 self-monitored blood glucose (smbg) readings per day. |
| PubMedID- 20809681 | Analysis of hemodialysis-associated hypoglycemia in patients with type 2 diabetes using a continuous glucose monitoring system. |
| PubMedID- 24853553 | This study assesses the impact of missed insulin doses and prevalence of mistimed and reduced insulin doses and mild hypoglycemia in patients with type 2 diabetes treated with basal insulin analogues in spain, and compares the data collected to pooled data from 8 other european countries (oecs). |
| PubMedID- 25782322 | It is concluded that evaluation of quality of life and hypoglycemia-related symptoms in patients with type 2 diabetes mellitus on basal-bolus insulin therapy allows for comprehensive estimation of the effectiveness of therapy on an individual basis. |
| PubMedID- 25589828 | Therefore, the identification of measures to prevent hypoglycemia in patients with type 2 diabetes is needed urgently. |
| PubMedID- 26407587 | Conclusions: nocturnal hypoglycemia in patients with type 2 diabetes caused a decrease in awakening response in the 4-8-h period following the event. |
| PubMedID- 24223662 | This regimen is more efficient and reduces the incidence of hypoglycemia in patients with type 2 diabetes, indicating that it is likely to be a promising treatment strategy for the disease. |
| PubMedID- 25931826 | The epidemiology of diabetes and ramadan (epidiar) study has reported a 7.5-fold increase in risk of hypoglycemia in patients with type 2 diabetes.2 however, this risk can be reduced by extensive diabetes education and pre-ramadan medication adjustments.1 hence, ramadan itself is not a risk, but poor education and use of medications which cause hypoglycemia with high dosages carries a risk. |
| PubMedID- 22374637 | Poor cognitive function and risk of severe hypoglycemia in type 2 diabetes: post hoc epidemiologic analysis of the accord trial. |
| PubMedID- 24185751 | Bariatric teams performing lsg for morbid obesity should heighten their sensitivity to postoperative hypoglycemia, even in patients with type 2 diabetes mellitus. |
| PubMedID- 22357185 | Likewise, long-term (52 weeks) treatment with the once-weekly formulation of exenatide (eqw) led to sustained improvements in glycemic control, in the presence of body weight reduction and low hypoglycemia event rates in patients with type 2 diabetes (3). |
| PubMedID- 23248198 | Presence of macroalbuminuria predicts severe hypoglycemia in patients with type 2 diabetes: a 10-year follow-up study. |
| PubMedID- 22956255 | Genetic variants in gckr, gipr, adcy5 and vps13c and the risk of severe sulfonylurea-induced hypoglycaemia in patients with type 2 diabetes. |
| PubMedID- 25922810 | However, the effect of structured education on the prevention of hypoglycemia in patients with type 2 diabetes has not been well studied. |
| PubMedID- 22646230 | The most common causes of hypoglycemia among patients with type 2 diabetes include the use of hypoglycemic medications [4], inadequate caloric intake, exercise, errors with use of medications, and intercurrent illnesses. |
| PubMedID- 23981060 | Background: dpp-4 inhibitors (dpp4-i) have been shown to provide non-inferior glycaemic control compared with sulfonylureas (su), but result in a reduction of body weight and a significantly lower risk of hypoglycaemia in patients with type 2 diabetes. |
| PubMedID- 23075070 | In people with insulin-treated type 2 diabetes, recall of severe hypoglycaemia is similarly robust over a period of one year[30] but the reliability of recall of mild hypoglycaemia has not been examined and is unlikely to be preserved. |
| PubMedID- 21790477 | Relationship between interstitial and blood glucose during hypoglycemia in subjects with type 2 diabetes. |
| PubMedID- 26354059 | This study is the first to examine electrolyte profiles during severe hypoglycemia in patients with type 2 diabetes in clinical practice. |
| PubMedID- 20456169 | Some therapeutic regimens are associated with a significantly increased risk of hypoglycaemia in patients with type 2 diabetes (1,3,4,19). |
| PubMedID- 20539226 | Recent findings: sglt2 inhibitors enhance glucose excretion and improve glycemic control in patients with type 2 diabetes in the absence of clinically relevant hypoglycemia or sustained changes in volume status or glomerular filtration rate. |
| PubMedID- 21231863 | The objective of this study was to compare healthcare utilization, costs, adherence, and hypoglycemia rates in patients with type 2 diabetes mellitus (t2dm) initiating rapid-acting insulin analog (raia) using prefilled pen versus vial/syringe. |
| PubMedID- 25263824 | Quality of life and fear for hypoglycaemia in patients with type 2 diabetes mellitus. |
| PubMedID- 24186878 | Conclusions: long-term empagliflozin treatment provided sustained glycemic and weight control and was well tolerated with a low risk of hypoglycemia in patients with type 2 diabetes. |
| PubMedID- 22675341 | Due to this properties, the hormone reduces hyperglycemia without inducing hypoglycemia in patients with type 2 diabetes [3]. |
| PubMedID- 23226632 | The paucity of data on epidemiology of hypoglycemia in type 2 diabetes from clinical studies is of serious concern, particularly with most of the data generated being antecedent to other primary scientific objective(s). |
| PubMedID- 24612200 | Aims: to assess incidence rates (irs) of and identify risk factors for incident severe hypoglycaemia in patients with type 2 diabetes newly treated with antidiabetic drugs. |
| PubMedID- 22446170 | Effects of dapagliflozin, an sglt2 inhibitor, on hba(1c), body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy. |
| PubMedID- 19896233 | Aims: to compare total costs and risk of hypoglycemia in patients with type 2 diabetes (t2d) initiated on nph insulin versus glargine in a real-world setting. |
| PubMedID- 25685276 | The sulfonylurea use is significantly associated with severe hypoglycemia in patients with type 2 diabetes. |
| PubMedID- 26003888 | Incidence of hypoglycemia in patients with type 2 diabetes treated with gliclazide versus dpp-4 inhibitors during ramadan: a meta-analytical approach. |
| PubMedID- 20429797 | Conclusion: an intensive glucose control strategy can effectively reduce the risk of major cardiovascular events but at the expense of a significantly increased risk of severe hypoglycemia in patients with type 2 diabetes. |
| PubMedID- 23586474 | The association between adherence to oral anti-diabetic drugs and hypoglycaemia in persons with type 2 diabetes. |
| PubMedID- 24026211 | Other sglt2 inhibitors, dapagliflozin and empagliflozin, have also demonstrated efficacy in lowering hba1c and body weight with a low risk of hypoglycaemia in patients with type 2 diabetes [11–14]. |
| PubMedID- 23807922 | [23] demonstrated st depression and the flattening of the t wave during the episodes of insulin-induced hypoglycemia in patients with type 2 diabetes. |
| PubMedID- 21892855 | hypoglycemia in patients with type 2 diabetes using concomitant exenatide bid and long-acting insulin therapy. |
| PubMedID- 25698911 | Thus, the aim of the current analysis was to investigate the rates and predictors of documented hypoglycemia in patients with type 2 diabetes on various insulin treatment regimens in general and internal medicine practices. |
| PubMedID- 26163815 | In both type 1 and type 2 diabetes, recurrent episodes of treatment-associated hypoglycemia impair how well the brain can sense and respond to subsequent episodes of hypoglycemia. |
| PubMedID- 25125745 | However, intensifying glucose control in both type 1 and type 2 diabetes increases the risk of developing hypoglycemia, one of the most feared complications of people with the disease. |
| PubMedID- 26025695 | We describe a type 2 diabetes patient with persistent hypoglycemia caused by sulfonylurea misuse on top of a dpp-4 inhibitor. |
| PubMedID- 23959567 | Cardiovascular autonomic dysfunction predicts severe hypoglycemia in patients with type 2 diabetes: a 10-year follow-up study. |
| PubMedID- 23637538 | Table 1 summarizes the most common causes and risk factors for hypoglycemia in patients with type 2 diabetes. |
| PubMedID- 24548693 | Aims: the global attitude of patients and physicians 2 (gapp2) survey sought to address gaps in understanding about real-world basal insulin-taking behaviour and self-treated hypoglycaemia in patients with type 2 diabetes mellitus. |